Long-term results of International Breast Cancer Study Group Trial Viii: Adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2216-2226

  Karlsson, P ^a   Sun, Z ^b   Braun, D ^b   Price, K N ^c   Castiglione gertsch, M ^d   Rabaglio, M ^e   Gelber, R D ^c   Crivellari, D ^f   Collins, J ^g   Murray, E ^h   Zaman, K ⁱ   Colleoni, M ^j   Gusterson, B A ^k   Viale, G ^l   Regan, M M ^b   Coates, A S ^m,n   Goldhirsch, A ^j,o  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

^l UNIVERSITY OF MILAN   (Italy)

^m International Breast Cancer Study Group   (Switzerland)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

^o ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

more..

Author keywords

Amenorrhea; Breast cancer; Chemotherapy; Goserelin; Hormonal therapy; Node negative

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; LYMPH NODE NEGATIVE BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 80053151094     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq735     Document Type: Article

References (22)

1. Dowsett M, Goldhirsch A, Hayes DF et al. International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007; 9: R81.
2. Early Breast Cancer Clinical Trialists' Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Viale G, Regan MM, Maiorano E et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 2008; 26: 1404-1410.
4. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-1667.
5. Colozza M, Azambuja E, Cardoso F et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16: 1723-1739.
6. Viale G, Regan MM, Mastropasqua MG et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100: 207-212.
7. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
8. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95: 1833-1846.
9. Regan MM, Viale G, Mastropasqua MG et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 2006; 98: 1571-1581.
10. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127-2132.
11. Lazar AA, Cole BF, Bonetti M, Gelber RD. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: Subpopulation Treatment Effect Pattern Plot. J Clin Oncol 2010; 28: 4539-4544.
12. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332-1341.
13. Swain SM, Jeong JH, Geyer CE Jr et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065.
14. Swain SM, Jeong JH, Wolmark N. Amenorrhea from breast cancer therapy - not a matter of dose. N Engl J Med 2010; 363: 2268-2270.
15. Thürlimann B, Price KN, Gelber RD et al. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009; 113: 137-144.
16. Regan MM, Pagani O, Walley B et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008; 19: 1231-1241.
17. Bernhard J, Zahrieh D, Castiglione-Gertsch M et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients-the International Breast Cancer Study Group Trial VIII. J Clin Oncol 2007; 25: 263-270.
18. Davidson NE, O'Neill AM, Vukov CK et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005; 23: 5973-5982.
19. Price KN, Goldhirsch A. Clinical trial update: International Breast Cancer Study Group. Breast Cancer Res 2005; 7: 252-254.
20. National Cancer Institute. The TAILORx breast cancer trial. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=472066&protocolsearchid=7680044&version=healthprofessional#StudyIdInfo_CDR0000472066 (10 May 2010, date last accessed).
21. Viale G, Regan MM, Maiorano E et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 2008; 26: 1404-1410.
22. Colleoni M, Cole BF, Viale G et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, nodenegative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010; 28: 2966-2973.